A recent CNN Health article noted the clearance of a new Covid-19 antibody test that measures precise levels of antibodies in people who have recovered from the virus. The test is called COVID-SeroKlir, and it was developed by Kantaro Biosciences, a joint venture between Mount Sinai and RenalytixAI. It received the FDA’s emergency use authorization on November 25th.
Knowing precise antibody levels will help researchers learn more about the virus and what the existence of antibodies could mean for recovery and immunity, as well as informing vaccine development.
